<DOC>
	<DOCNO>NCT02122913</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1 study orally administer larotrectinib adult subject advance solid tumor progress non responsive available therapy standard available curative therapy exists .</brief_summary>
	<brief_title>Oral TRK Inhibitor LOXO-101 Treatment Advanced Adult Solid Tumors</brief_title>
	<detailed_description>The trial conduct 2 part : initial dose escalation phase larotrectinib subject advance solid tumor . This followed expansion phase solid tumor subject NTRK fusion , document alteration TRK gene investigator documentation perceive benefit TRK target agent . During escalation phase , larotrectinib take daily ( QD ) twice daily ( BID ) . During expansion phase , larotrectinib dose select escalation phase explore approximately 40 additional subject . The objective dose escalation phase determine safety , tolerability , pharmacokinetic profile , recommend dose orally administer larotrectinib . The objective expansion phase well characterize safety efficacy larotrectinib patient specific NTRK gene protein , patient , opinion Investigator , may derive benefit highly selective TRK inhibitor larotrectinib .</detailed_description>
	<criteria>Escalation Phase [ Inclusion ] Locally advance metastatic adult solid tumor progress nonresponsive available therapy , unfit standard chemotherapy standard available curative therapy exist ; ECOG score 0 , 1 2 ; Adequate hematologic , hepatic , renal function ; Expansion Phase [ Inclusion ] Escalation Phase inclusion criterion Evidence NTRK TRK molecular characteristic specify cohort , NTRK translocation , amplification , mutation alteration may interfere TRK signal previously determine prior test Clinical Laboratory Improvement Amendments ( CLIA ) certify equivalent certified laboratory . Additionally , patient , opinion clinical judgement local Investigator , may derive benefit target TRK inhibitor like larotrectinib , may also enroll . Exclusion ( Escalation Expansion ) â€¢ Current treatment strong cytochrome P450 ( CYP ) 3A4 inhibitor inducer ( EIAEDs dexamethasone CNS tumor metastasis , stable dose , allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TRK</keyword>
	<keyword>TRKA</keyword>
	<keyword>TRKB</keyword>
	<keyword>TRKC</keyword>
	<keyword>NTRK1</keyword>
	<keyword>NTRK2</keyword>
	<keyword>NTRK3</keyword>
	<keyword>larotrectinib</keyword>
	<keyword>NTRK fusion positive</keyword>
	<keyword>NTRK gene rearrangement</keyword>
	<keyword>NTRK1 fusion</keyword>
	<keyword>NTRK2 fusion</keyword>
	<keyword>NTRK3 fusion</keyword>
	<keyword>NTRK1 gene rearrangement</keyword>
	<keyword>NTRK2 gene rearrangement</keyword>
	<keyword>NTRK3 gene rearrangement</keyword>
	<keyword>ETV6-NTRK3</keyword>
	<keyword>fusion</keyword>
	<keyword>tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>CNS tumor</keyword>
	<keyword>central nervous system tumor</keyword>
	<keyword>TRK fusion</keyword>
	<keyword>ETV6</keyword>
	<keyword>ETV6 fusion</keyword>
	<keyword>ETV6 gene rearrangement</keyword>
	<keyword>solid CNS tumor</keyword>
	<keyword>Advanced CNS tumor</keyword>
	<keyword>Primary CNS tumor</keyword>
	<keyword>Metastatic CNS tumor</keyword>
	<keyword>LOXO-101</keyword>
</DOC>